Antiviral chemotherapy 5 : new directions for clinical application and research
著者
書誌事項
Antiviral chemotherapy 5 : new directions for clinical application and research
（Advances in experimental medicine and biology, v. 458）
Kluwer Academic/Plenum Publishers, c1999
- タイトル別名
-
Antiviral chemotherapy five
大学図書館所蔵 件 / 全11件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
"Proceedings of the Fifth Triennial Symposium on New Directions in Antiviral Chemotherapy, held November 13-15, 1997, in San Francisco, California"--T.p. verso
Includes bibliographical references and index
内容説明・目次
内容説明
Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in cubation period of active HIV infection, when the infection is clinically latent, is now un derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both.
目次
1. Overview of HBV Therapy.- 2. Lamivudine Therapy of Chronic Hepatitis B.- 3. Famciclovir Update: Chronic Hepatitis B.- 4. Current Status of Antiviral Therapy for Chronic Hepatitis C.- 5. Prevention and Treatment of Respiratory Syncytial Virus Infections.- 6. Update on Influenza and Rhinovirus Infections.- 7. Pleconaril: A Broad Spectrum Antipicornaviral Agent.- 8. Management of CMV Infections in HIV-Infected Patients.- 9. Management of Cytomegalovirus Infections in Blood and Marrow Transplant Recipients.- 10. Cidofovir: Review of Current and Potential Clinical Uses.- 11. Oral Ganciclovir.- 12. Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease.- 13. Famciclovir/Penciclovir.- 14. Valaciclovir Update.- 15. Therapeutic Approaches to the Management of Herpes Zoster.- 16. Management of Varicella-Zoster Virus Infections in Children.- 17. Failure of HIV-1 Protease Inhibitors to Fully Suppress Viral Replication: Implications for Salvage Therapy.- 18. New Reverse Transcriptase Inhibitors.- 19. HIV Viral Load Monitoring.- 20. Post-Exposure Prophylaxis for HIV.- 21. Antiretroviral Therapy in Primary HIV.- 22. Initial Treatment for HIV Infection: When, Why, and with What?.- 23. Strategies for Second-Line Antiretroviral Therapy in Adults with HIV Infection.
「Nielsen BookData」 より
